ClinicalTrials.gg
CompletedNCT03792555Updated Mar 17, 2025Results posted

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

A Phase 2 interventional study of Paltusotine and Placebo in Acromegaly, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 11 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.

02

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • ACROBAT
  • EVOLVE
  • Paltusotine
03

In context

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

This study's enrollment of 13 is below the median of 43 across 115 interventional studies indexed under Acromegaly.

Browse Acromegaly studies →

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects 18 to 75 years of age
  2. Confirmed diagnosis of acromegaly that is controlled on stable doses of octreotide LAR or lanreotide depot
  3. Females must be non-pregnant and non-lactating, and either surgically sterile, , or using effective method(s) of
  4. Willing to provide signed

Exclusion criteria

Exclusion Criteria:

  1. Treatment naïve acromegaly subjects
  2. Prior treatment with paltusotine
  3. Pituitary surgery within 6 months prior to Screening or radiation therapy at any time prior to the study entry. Pituitary radiation therapy (within 3 to 4 years or more than 4 years prior to study entry) with recently documented elevated IGF-1 may be eligible.
  4. History or presence of except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years.
  5. Use of any drug within the past 30 days or 5 half-lives, whichever is longer
  6. Positive test at Screening for , surface antigen (HBsAg) or antibody (HCV-Ab) or has a history of a positive result
  7. History of alcohol or substance abuse in the past 12 months
  8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study
  9. Cardiovascular conditions or medications associated with prolonged or those which predispose subjects to heart rhythm abnormalities.
  10. Subjects with symptomatic cholelithiasis
  11. Subjects with abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study
  12. Subjects who have been taking the following prior medications: pegvisomant (within the last 3 months), dopamine agonists (within the last 3 months) and pasireotide LAR (within the last 6 months)
  13. Subjects taking octreotide LAR at a dose higher than 40 mg or lanreotide depot at a dose higher than 120 mg
  14. Subjects who usually take octreotide LAR or lanreotide depot less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Paltusotine

    Drug: Paltusotine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Paltusotine, capsules, once daily by mouth

    Also known as: CRN00808

  • DrugPlacebo

    Placebo, capsules, once daily by mouth

06

What researchers measure

Primary outcomes

  1. Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13

    Proportion of subjects who meet responder criteria (based on the mean of two consecutive IGF-1 measurements ≤ upper limit of normal \[ULN\])

    Time frame: 13 Weeks

Secondary outcomes

  1. Change in IGF-1 Levels

    Change in IGF-1 levels between RWP Baseline/Week 10 and Week 13

    Time frame: From Week 10 to Week 13

  2. Change in Growth Hormone (GH) Levels

    Change in growth hormone levels between RWP Baseline/Week 8 and Week 13

    Time frame: From Week 8 to Week 13

  3. Change in Total ASD Score Between RWP Baseline/Week 10 and Week 13

    Measured by total Acromegaly symptom diary (ASD) score from W10-W13. ASD is a sponsor-developed daily diary to assess important acromegaly symptoms from the patient perspective. It covers 7 symptoms (headache pain, joint pain, sweating, fatigue, weakness in legs, swelling, and numbness or tingling). Patients rate the severity of each experience in the past 24 hours on an 11-point numeric scale that ranges from 0 (no symptom) to 10 (worst symptom). A weekly average ASD score is calculated for each item as the sum of the item responses for a specific item over the course of the study week divided by the number of days on which the item was completed. The weekly average ASD total score is calculated by computing the sum of the weekly average item scores for the 7 items (total range from 0 to 70), where higher score = higher symptom severity.

    Time frame: From Week 10 to Week 13

07

Results

Posted Mar 17, 2025
Limitations and caveats
Due to small sample size, a number of exploratory endpoints were defined but not summarised. All primary and secondary endpoints are reported.

Participant flow

Medically stable male and female subjects 18 to 75 years of age, inclusive, with a confirmed acromegaly diagnosis that was controlled on a stable approved dose of octreotide LAR or lanreotide depot. At a minimum, there had to be documentation available of a pituitary tumour and elevated IGF-1 in the past.

Screening Period: 4-6 Weeks
Participant flow — Screening Period: 4-6 Weeks
MilestoneTitration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not Randomized
Started346
Completed346
Not completed000
Titration Period: up to 9 Weeks
Participant flow — Titration Period: up to 9 Weeks
MilestoneTitration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not Randomized
Started346
Completed345
Not completed001
Withdrew: Covid-19001
Randomized Withdrawal: up to 4 Weeks
Participant flow — Randomized Withdrawal: up to 4 Weeks
MilestoneTitration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not Randomized
Started345
Completed340
Not completed005
Withdrew: Participants who did not meet randomization criteria did not enter the randomized withdrawal period.005
Follow-up Period: up to 4 Weeks
Participant flow — Follow-up Period: up to 4 Weeks
MilestoneTitration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not Randomized
Started345
Completed335
Not completed010
Withdrew: Covid-19010

Outcome measures

PrimaryResponder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13

Proportion of subjects who meet responder criteria (based on the mean of two consecutive IGF-1 measurements ≤ upper limit of normal \[ULN\])

Time frame:
13 Weeks
Reported as:
Number · percentage of responders
Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13
percentage of respondersRandomized Withdrawal Period: PaltusotineRandomized Withdrawal Period: PlaceboRandomized Withdrawal Period: Not Randomized
Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 1366.7 (9.4 to 99.2)25.0 (0.6 to 80.6)16.7 (0.4 to 64.1)
SecondaryChange in IGF-1 Levels

Change in IGF-1 levels between RWP Baseline/Week 10 and Week 13

Time frame:
From Week 10 to Week 13
Reported as:
Mean · percent change in IGF1
Change in IGF-1 Levels
percent change in IGF1Randomized Withdrawal Period: PaltusotineRandomized Withdrawal Period: PlaceboRandomized Withdrawal Period: Not Randomized
Change in IGF-1 Levels4.04 ± 5.06448.17 ± 41.408—
SecondaryChange in Growth Hormone (GH) Levels

Change in growth hormone levels between RWP Baseline/Week 8 and Week 13

Time frame:
From Week 8 to Week 13
Reported as:
Mean · percent change in GH
Change in Growth Hormone (GH) Levels
percent change in GHRandomized Withdrawal Period: PaltusotineRandomized Withdrawal Period: PlaceboRandomized Withdrawal Period: Not Randomized
Change in Growth Hormone (GH) Levels71.96 ± 48.865108.30 ± 179.977—
SecondaryChange in Total ASD Score Between RWP Baseline/Week 10 and Week 13

Measured by total Acromegaly symptom diary (ASD) score from W10-W13. ASD is a sponsor-developed daily diary to assess important acromegaly symptoms from the patient perspective. It covers 7 symptoms (headache pain, joint pain, sweating, fatigue, weakness in legs, swelling, and numbness or tingling). Patients rate the severity of each experience in the past 24 hours on an 11-point numeric scale that ranges from 0 (no symptom) to 10 (worst symptom). A weekly average ASD score is calculated for each item as the sum of the item responses for a specific item over the course of the study week divided by the number of days on which the item was completed. The weekly average ASD total score is calculated by computing the sum of the weekly average item scores for the 7 items (total range from 0 to 70), where higher score = higher symptom severity.

Time frame:
From Week 10 to Week 13
Reported as:
Mean · Total ASD score change -units on a scale
Change in Total ASD Score Between RWP Baseline/Week 10 and Week 13
Total ASD score change -units on a scaleRandomized Withdrawal Period: PaltusotineRandomized Withdrawal Period: PlaceboRandomized Withdrawal Period: Not Randomized
Change in Total ASD Score Between RWP Baseline/Week 10 and Week 131.571 ± 3.10047.962 ± 7.1591—

Adverse events

Collected over Duration of participation for each subject after obtaining a signed informed consent was up to 23 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Analysis Set/Titration Period - Paltusotine0/13 (0%)0/13 (0%)8/13 (61.5%)
Randomized Withdrawal Period - Paltusotine0/3 (0%)0/3 (0%)3/3 (100%)
Randomized Withdrawal Period - Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Total Paltusotine0/13 (0%)0/13 (0%)10/13 (76.9%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventSafety Analysis Set/Titration Period - PaltusotineRandomized Withdrawal Period - PaltusotineRandomized Withdrawal Period - PlaceboTotal Paltusotine
ArthralgiaMusculoskeletal and connective tissue disorders1/130/32/41/13
HypertensionVascular disorders0/131/30/41/13
Blood triglycerides increasedInvestigations0/131/30/41/13
HeadacheNervous system disorders3/131/30/44/13
FatigueGeneral disorders2/131/30/43/13
PainGeneral disorders0/131/30/41/13
Back painMusculoskeletal and connective tissue disorders0/131/31/41/13
MyalgiaMusculoskeletal and connective tissue disorders0/131/30/41/13
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/130/31/40/13
ParaesthesiaNervous system disorders2/130/31/42/13

Baseline characteristics

The Baseline Analysis Population includes all subjects who received treatment in the titration period. This includes subjects who were randomized in the randomized withdrawal period to receive placebo or continue receiving paltusotine and subjects who were not randomized and continued receiving paltusotine. The primary endpoint is presented for all subjects. Secondary endpoints are presented only for the randomized subjects as the RW baseline was not applicable to the non-randomized subjects.

Age, Categorical
Age, Categorical(Participants)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
<=18 years0000
Between 18 and 65 years1449
>=65 years2024
Age, Continuous
Age, Continuous(years)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
Mean65.0 ± 3.0038.8 ± 8.6657.7 ± 11.4853.5 ± 13.76
Sex: Female, Male
Sex: Female, Male(Participants)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
Female2136
Male1337
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
Hispanic or Latino1023
Not Hispanic or Latino24410
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
White34512
American Indian or Alaska Native0000
Asian0000
Black or African American0000
Native Hawaiian or Other Pacific Islander0000
Other0011
UGT1A1 Genotype
UGT1A1 Genotype(Participants)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
*1/*11225
*1/*802125
*80/*800112
Not reported0011
UGT1A1 Phenotype
UGT1A1 Phenotype(Participants)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
Normal Metabolizer1225
Intermediate Metabolizer2125
Poor Metabolizer0112
Not reported0011
Height
Height(cm)Titration Period: Paltusotine, Then Randomized Withdrawal Period: PaltusotineTitration Period: Paltusotine, Then Randomized Withdrawal Period: PlaceboTitration Period: Paltusotine, Then Not RandomizedTotal
Mean163.07 ± 8.100181.90 ± 14.461167.73 ± 12.502171.02 ± 13.748

3 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • Ohio State University
    Columbus, Ohio 43210, United States
  • The Research Institute of Dallas
    Dallas, Texas 10260, United States
  • CETI - Centro de Estudos em Terapias Inovadoras
    Curitiba, Brazil
  • CPQuali Pesquisa Clinica
    São Paulo, Brazil
  • General Hospital of Athens "Gennimatas"
    Athens, Greece
  • Semmelweis University Faculty of Medicine
    Budapest, Hungary
  • University of Pécs Medical School
    Pécs, Hungary
  • Endocrine, Diabetes and Research Centre, Wellington Hospital
    Wellington, New Zealand
  • The Centre of Postgraduate Medical Education
    Warsaw, Poland
  • Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
    Belgrade, Serbia
  • National Institute of Endocrinology and Diabetology
    Ľubochňa, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jul 2020, 16 months.

Results were first posted in Mar 2025, 4 years 8 months after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2018
First posted
Jan 3, 2019
StartActual
Mar 11, 2019
Primary completionActual
Jul 15, 2020
CompletionActual
Aug 12, 2020
Results delay requested
Jul 13, 2021
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03792555
Responsible party
Sponsor
First posted
Jan 3, 2019
Start date
Mar 11, 2019
Primary completion
Jul 15, 2020
Completion
Aug 12, 2020
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paltusotine

Start the discussion